Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST) has been recently reported after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present a case of a patient with fulminant CVST and thrombocytopenia after receiving the ChAdOx1 nCoV-19 vaccine. Although the patient received immediate anticoagulant and intravenous immune globulin treatment, he died within 24 h after hospital admission. VITT and CVST are rare conditions; however, the course may be fatal. Therefore, clinicians should be familiarized with the clinical and laboratory features of VITT.
All Keywords
【저자키워드】 COVID-19, COVID-19 vaccine, thrombocytopenia, VITT, CVST, 【초록키워드】 Treatment, SARS-CoV-2, coronavirus, vaccination, thrombosis, immune, Patient, Hospital admission, ChAdOx1 nCoV-19 vaccine, Anticoagulant, intravenous, acute respiratory syndrome, clinician, thrombotic, venous, Course, died, reported, the patient, receiving, laboratory feature, 【제목키워드】 ChAdOx1 nCoV-19, cerebral, report, Sinus,
【저자키워드】 COVID-19, COVID-19 vaccine, thrombocytopenia, VITT, CVST, 【초록키워드】 Treatment, SARS-CoV-2, coronavirus, vaccination, thrombosis, immune, Patient, Hospital admission, ChAdOx1 nCoV-19 vaccine, Anticoagulant, intravenous, acute respiratory syndrome, clinician, thrombotic, venous, Course, died, reported, the patient, receiving, laboratory feature, 【제목키워드】 ChAdOx1 nCoV-19, cerebral, report, Sinus,